Armin Schulz
Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.
After graduating, he worked as an IT consultant for a listed company before becoming self-employed, during which time he worked for various DAX-listed companies and a large Swiss insurance company, among others.
Since 2009, he has been exclusively involved in the capital markets, where he was able to gain experience as a day and swing trader, in investor relations and at board level. He was able to live out his passion for numbers in the controlling department of a securities trading house.
For him, fundamental analysis paired with the correct reading of the price action of a market provides the basis for successful trading.
Commented by Armin Schulz
Commented by Armin Schulz on September 22nd, 2025 | 07:00 CEST
Your gold playbook: Profit from rising prices with Barrick Mining, Dryden Gold, and Newmont
Gold is experiencing a spectacular rally, driven by interest rate cuts from the US Federal Reserve and an uncertain economic outlook. As a safe haven, the precious metal is benefiting directly from this monetary policy shift, which is lowering opportunity costs for investors and fueling demand as a hedge against inflation. This ideal setup could help stabilize the price at a high level and offers attractive opportunities. Against this backdrop, it is worth taking a look at the strategies of Barrick Mining, Dryden Gold and Newmont.
Read
Commented by Armin Schulz on September 19th, 2025 | 07:05 CEST
BYD expands, Pasinex Resources acquires, Puma attracts buyers: How you can profit from the latest news
While global markets are in flux, two companies are pursuing proactive strategies for future growth. An e-mobility pioneer is skillfully circumventing trade barriers by expanding local production. A mining explorer is securing control of valuable resources through a complete takeover. At the same time, a major sportswear brand has become a takeover target itself, facing increased speculation. The strategic moves by BYD and Pasinex Resources, as well as the ongoing debate about Puma's future, offer key insights for investors. We take a closer look at where to invest right now.
Read
Commented by Armin Schulz on September 18th, 2025 | 07:15 CEST
Novo Nordisk, PanGenomic Health and Pfizer - Who are the winners of the digital health revolution?
The disruptive force of the digital health revolution is fundamentally changing the healthcare industry. Artificial intelligence, data-driven therapies, and digital diagnostics are opening up billion-dollar markets and catapulting agile players to the forefront. These pioneers are setting new standards in patient-centered care and generating exponential growth in the process. This ecosystem opens up unique opportunities for strategic investors. Today, we take a look at Novo Nordisk's restructuring, PanGenomic Health's AI-driven innovations, and the political uncertainties at Pfizer.
Read
Commented by Armin Schulz on September 17th, 2025 | 07:10 CEST
Rheinmetall, Almonty Industries, RENK: The next wave of the defense stock mega boom is rolling in
Geopolitical tensions and a paradigm shift toward increased national security are fueling a sustained boom in the defense industry. Rising budgets worldwide are ensuring full order books and unprecedented growth prospects for specialized companies. This development is making defense stocks one of the most dynamic, albeit controversial, investment themes. Three listed companies that are perfectly positioned to capitalize on this environment are Rheinmetall, Almonty Industries, and the RENK Group.
Read
Commented by Armin Schulz on September 16th, 2025 | 07:20 CEST
Building wealth with network effects and AI: How Palantir, MiMedia, and Alibaba are making investors rich
The global economy is being driven by a new type of company: scalable platform ecosystems with predictable, recurring revenues. They leverage network effects for exponential growth and are resilient to economic fluctuations. These disruptive business models, at the intersection of AI, data, and digital connectivity, generate steady cash flows and define the investment opportunities of tomorrow. Three companies that perfectly embody this strategy are Palantir, MiMedia Holdings and Alibaba.
Read
Commented by Armin Schulz on September 15th, 2025 | 07:25 CEST
Beyond FAANG, German tech companies such as SAP, Finexity and TeamViewer also offer potential for your portfolio
While US tech giants like Meta and Google dominate the headlines, other technology companies in Germany receive little attention. But here too, on the other side of the Atlantic, innovative companies with disruptive technologies and robust business models are shaping the future and offering unique opportunities for capital growth. Reason enough to take a closer look at three German companies: SAP, Finexity and TeamViewer. We analyze the strategic decisions and innovations that will shape the next investment success story.
Read
Commented by Armin Schulz on September 12th, 2025 | 07:05 CEST
Investing in the future of medicine: A look at Novo Nordisk, NetraMark Holdings and Evotec
AI is completely transforming the pharmaceutical industry. Modern algorithms sift through vast amounts of data, identify promising therapeutic approaches, and advance drug development at record speed. This increase in efficiency is an absolute game changer. Not only does it save billions, but it also significantly increases success rates and catapults agile companies to the forefront. While cumbersome large corporations laboriously digitize their research departments, disruptive start-ups with innovative AI platforms are shaking up the market. It is precisely this dynamic that presents unique opportunities for investors, if they know how to decipher them. Today, we take a closer look at Danish pharmaceutical giant Novo Nordisk, AI specialist NetraMark Holdings, and German research service provider Evotec.
Read
Commented by Armin Schulz on September 12th, 2025 | 07:00 CEST
NATO attack!? How to IMMEDIATELY arm your portfolio with RENK Group, Antimony Resources and Deutz
The presence of Russian drones on Polish territory - a NATO member - marks a dangerous escalation in the security situation. With a swift ceasefire in Ukraine increasingly seeming a distant prospect, investors should refocus their attention on defense stocks. This new escalation is directly fueling demand for modern defense technology and opening up tangible opportunities for investors in specialized suppliers. Three companies that stand to benefit directly from this trend are RENK Group, Antimony Resources and Deutz.
Read
Commented by Armin Schulz on September 11th, 2025 | 07:15 CEST
The Hidden Champions of 2025: Puma, Sranan Gold and AMD – Where it might be worth getting in
As an investor, it is often wise to find hidden gems rather than buy expensive market leaders. While large corporations are often overvalued, undervalued small caps offer unique opportunities. Whether as turnaround candidates, commodity gems, or technology leaders, these specialized companies have the potential to dominate their niches and initiate a quiet catch-up rally. For savvy investors, this second tier is the real source of above-average returns. Three promising candidates that embody this profile are sporting goods manufacturer Puma, gold explorer Sranan Gold, and chip designer AMD. Let's take a look at their current situation.
Read
Commented by Armin Schulz on September 11th, 2025 | 07:10 CEST
Forget weight loss injections! BioNxt Solutions is unsettling Big Pharma, but could become an important partner
There is a catch with weight loss injections: they are injections. Studies show that adherence to treatment drops dramatically after one year. What if the blockbuster drug could simply be dissolved under the tongue? That is precisely what BioNxt Solutions is working on. With its patented dissolvable film technology, the Canadian-German biotech company not only aims to revolutionize obesity therapy but also make strides in multiple sclerosis treatment. The approach could transform entire markets.
Read